glp 1 agonist shortage Shortages improve for Lilly's GLP-1 weight loss drugs, bumping sales forecast by $3bn GLP-1 Antagonists Increase Plan Drug

We aimed to contrast addon therapy, adherence, and changes in biomarkers, 1 year after treatment initiation with GLP1 RA or metformin

aHR, adjusted hazard ratio

Cancer, aging and an unknown number of other changes can ensue

[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jdar E., Leiter L.A., Lingvay I., Rosenstock J., Seufert J., Warren M.L., et al

This broadened inclusion criteria allowed for a more comprehensive understanding of drug effects in high-risk groups and supported the expansion of GLP-1R agonist indications beyond glycemic control to include cardiovascular and renal benefits

Innovations in oral GLP-1 delivery and long-acting drugs, coupled with strategic acquisitions, further enhance market opportunities